Abstract:Ethnopharmacological relevance: Numerous studies have provided evidence supporting the significant roles of icariin, in the prevention of multiple chronic diseases like diabetes, liver fibrosis, cardiac fibrosis, renal fibrosis, and pulmonary fibrosis. In particular, Icariside II (ISE II), a prominent flavonoid glycoside derived from Epimedium brevicornum Maxim, the principal metabolite of icariin, has demonstrated noteworthy anti-inflammatory and anti-oxidant properties, along with its ability to protect against lung remodeling. However, the research exploring ISE II's application in treating pulmonary fibrosis remains limited. Aim of the study: The aim of this study was to assess the therapeutic efficacy of ISE II in models of pulmonary fibrosis, while also investigating its potential mechanisms of action in cell signaling pathways. Materials and methods: An in vitro model of pulmonary fibrosis was established by treating NIH-3T3 cells with transforming growth factor-& beta;1 (TGF-& beta;1). Western blot, RT-qPCR, and scratch test were performed to assess the effect of ISE II. In addition, a murine model of pulmonary fibrosis was induced by intratracheal instillation of bleomycin, and the therapeutic effect of ISE II was tested by orally administering ISE II at a dose of 10 mg/kg. Three weeks later, lung function, micro-CT, hydroxyproline content, pathological staining, and cytokines detection of BALF or serum were used to assess the anti-fibrosis effects of ISE II. Next, immunofluorescence staining, flow cytometry, and in vivo transcriptomics were used to investigate the underlying mechanisms of action. Results: Our data revealed a significant inhibitory effect of ISE II on the upregulation of & alpha;-smooth muscle actin (& alpha;-SMA) and collagen production induced by TGF-& beta;1 in fibroblasts. Meanwhile, ISE II exerted a therapeutic effect against bleomycin-induced pulmonary fibrosis in mice by improving lung function, decreasing collagen deposition, and reducing the expression of interleukin (IL)-1 & beta;, tumor necrosis factor & alpha; (TNF-& alpha;), TGF-& beta;1 and plateletderived growth factor (PDGF) in serum and bronchoalveolar lavage fluid (BALF). Additionally, ISE II treatment effectively attenuated the infiltration of M2 macrophages, concurrently downregulating the expression level of M2 marker genes, such as CD206, arginase-1(Arg-1), and Chitinase-Like Protein 3 (YM-1). Importantly, we observed a statistically significant reduction in the M2 phenotype of interstitial macrophages (IMs). However, the impact of ISE II on the M2 polarization of alveolar macrophages (AMs) did not reach statistical significance. Lastly, transcriptome sequencing results suggested that the anti-pulmonary fibrosis effects of ISE II may be mediated by the suppression of the WNT/& beta;-catenin signaling pathway, which modulated M2 polarization in macrophages and contributed to the amelioration of pulmonary fibrosis. By immunohistochemical analysis, it was verified that ISE II treatment dramatically inhibited the activation of & beta;-catenin in fibrosis murine. Conclusion: Our findings indicated that ISE II exerted anti-fibrotic effects by inhibiting pro-fibrotic macrophage polarization. The underlying mechanism of action might be mediated by modulating the WNT/& beta;-catenin signaling pathway to inhibit the M2 program in IMs.

Icariside I reduces breast cancer proliferation, apoptosis, invasion, and metastasis probably through inhibiting IL-6/STAT3 signaling pathway

Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells.

Anticancer Effect of Icaritin on Human Lung Cancer Cells Through Inducing S Phase Cell Cycle Arrest and Apoptosis.

Icariside II inhibits the EMT of NSCLC cells in inflammatory microenvironment via down-regulation of Akt/NF-κB signaling pathway.

Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape

Icaritin Derivative IC2 Induces Cytoprotective Autophagy of Breast Cancer Cells via SCD1 Inhibition

Icariside I enhances the effects of immunotherapy in gastrointestinal cancer via targeting TRPV4 and upregulating the cGAS-STING-IFN-I pathway

Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions

Icariside II Potentiates the Anti-Pd-1 Antitumor Effect by Reducing Chemotactic Infiltration of Myeloid-Derived Suppressor Cells into the Tumor Microenvironment Via ROS-mediated Inactivation of the SRC/ERK/STAT3 Signaling Pathways.

Icariin Regulates EMT and Stem Cell-Like Character in Breast Cancer through Modulating lncRNA NEAT1/TGFβ/SMAD2 Signaling Pathway

Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells.

Icariside Ⅱ Attenuates Bleomycin-Induced Pulmonary Fibrosis by Modulating Macrophage Polarization

Icariside II: Anticancer Potential and Molecular Targets in Solid Cancers

Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma

Icariin‐induced inhibition of SIRT6/NF‐κB triggers redox mediated apoptosis and enhances anti‐tumor immunity in triple‐negative breast cancer

Preparation of icariside I and icariside II, an exploration of their protective mechanism against cyclophosphamide-induced bone marrow suppression in mice, and their regulatory effects on immune function

Study on the Regulatory Mechanism and Experimental Verification of Icariin for the Treatment of Ovarian Cancer Based on Network Pharmacology

Icariside II suppressed tumorigenesis by epigenetically regulating the circβ-catenin-Wnt/β-catenin axis in colorectal cancer

Icaritin promotes tumor T‐cell infiltration and induces antitumor immunity in mice

The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors.

Icariin Suppresses Cell Cycle Transition and Cell Migration in Ovarian Cancer Cells